ProKidney shares are trading lower after the company announced opperational updated and progress in European and U.S. Clincial Trials for CKD therapy, rilparencel. Also, Jefferies maintained a Buy rating on the stock and lowered its price target from $15 to $6.
Portfolio Pulse from Benzinga Newsdesk
ProKidney shares are trading lower following an operational update and progress report on European and U.S. clinical trials for its CKD therapy, rilparencel. Jefferies maintained a Buy rating but lowered the price target from $15 to $6.
June 10, 2024 | 7:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ProKidney shares are trading lower after the company provided an operational update and progress report on its CKD therapy, rilparencel. Jefferies maintained a Buy rating but significantly lowered the price target from $15 to $6.
The operational update and clinical trial progress report likely raised concerns among investors, leading to a drop in share price. Additionally, Jefferies' decision to lower the price target from $15 to $6, despite maintaining a Buy rating, suggests a more cautious outlook on the stock, contributing to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100